ARS Pharmaceuticals has submitted a supplemental new drug application to the FDA for neffy 1 mg, aiming to treat type 1 allergic reactions in children weighing between 33 lb and 66 lb. Neffy is an epinephrine nasal spray that eliminates the need for needles, reducing fear and accidental needle-related injuries. The ease of use, small size, and temperature resistance make neffy a convenient option for families with children with severe allergies. ARS Pharmaceuticals is also focusing on developing nasal spray treatments for other type 1 hypersensitivity reactions, such as urticaria. Access and affordability for neffy are supported through the neffyConnect program.
Source link
Company seeks to expand neffy FDA approval to more pediatric patients
